Cancer Stem Cells: What Do We Know about Them?

Abstract

During past decades, survival rates in cancer patients have drastically improved due to the successful development of novel, promising chemical compounds and therapeutic schedules [...]

An integrative model of cancer cell differentiation with immunotherapy*

“…Despite this, this model agrees with what is expressed by different investigations on the practice focused on attacking cytotoxic cells on CSCs (primarily those already partially or totally differentiated [90]). Mainly, in accordance with recent research, CSC-specific therapy (for example, by identifying CSC markers [91]) contributes to effective treatment, although it must be complemented with other therapies [69,92]. A consistent result with our model, since a considerable decrease in the number of cancer cells, is achieved although not eliminating them completely [93,94].…”

Hypomethylation‐associated Sox11 upregulation promotes oncogenesis via the PI3K/AKT pathway in OLP‐associated OSCC

“… 67 CSCs are a small population of tumour cells with malignant biological behaviours such as promoting tumour malignant proliferation, accelerating tumour metastasis, inducing tumour drug resistance, and causing tumour recurrence, collectively referred to as stemness. 68 The stemness of CSCs is one of the crucial reasons for the poor prognosis of cancer. 69 Some studies have successfully isolated OSCC‐CSCs with the help of magnetic bead sorting technology.…”

“…In addition, OSCC has the vital characteristics of tissue heterogeneity and complex tumour microenvironment, which is associated with cancer stem cells (CSCs) 67 . CSCs are a small population of tumour cells with malignant biological behaviours such as promoting tumour malignant proliferation, accelerating tumour metastasis, inducing tumour drug resistance, and causing tumour recurrence, collectively referred to as stemness 68 . The stemness of CSCs is one of the crucial reasons for the poor prognosis of cancer 69 .…”

Simultaneous determination of paclitaxel and dasatinib in rat plasma and pharmacokinetic study on liquid chromatography‐tandem mass spectrometry

“…Triple‐negative breast cancer (TNBC) is still one of the most lethal cancers now and with high morbidity, deficiency of effective treatment, and poor patient outcomes, owing to the lack of expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 [1–5], in which circumstances, targeting the cancer stem cells is an approach to improve the cure rate of TNBC. Non‐receptor tyrosine kinases are a member of the family tyrosine kinases and have been considered a regulator of breast cancer stem cell metastasis [6–8]. In 2006, dasatinib was approved by the United States Food and Drug Administration as a new kind of multiple tyrosine kinase inhibitor used on imatinib mesylate drug resistance in patients with chronic myeloid leukemia and Philadelphia chromosome‐positive lymph cell leukemia.…”